Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $44.00.

A number of equities analysts have commented on the stock. Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective on the stock. TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Wedbush upped their price target on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ikarian Capital LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $6,574,000. Jain Global LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,774,000. Remedium Capital Partners LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,772,000. Boothbay Fund Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,204,000. Finally, Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth about $100,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $29.92 on Friday. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The business has a 50-day moving average of $26.46 and a two-hundred day moving average of $26.27. The stock has a market capitalization of $1.84 billion, a P/E ratio of -5.36 and a beta of 1.47.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, research analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.